166 related articles for article (PubMed ID: 33235818)
21. Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2.
Wada S; Tsunoda T; Baba T; Primus FJ; Kuwano H; Shibuya M; Tahara H
Cancer Res; 2005 Jun; 65(11):4939-46. PubMed ID: 15930316
[TBL] [Abstract][Full Text] [Related]
22. A Pilot Study of Post-Operative Adjuvant Vaccine for Advanced Gastric Cancer.
Fujiwara Y; Sugimura K; Miyata H; Omori T; Nakano H; Mochizuki C; Shimizu K; Saito H; Ashida K; Honjyo S; Nakamura Y; Yano M
Yonago Acta Med; 2017 Jun; 60(2):101-105. PubMed ID: 28701892
[TBL] [Abstract][Full Text] [Related]
23. Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer.
Aruga A; Takeshita N; Kotera Y; Okuyama R; Matsushita N; Ohta T; Takeda K; Yamamoto M
Clin Cancer Res; 2013 Apr; 19(8):2224-31. PubMed ID: 23479678
[TBL] [Abstract][Full Text] [Related]
24. Identification of a naturally processed HLA-A*0201 HPV18 E7 T cell epitope by tumor cell mediated in vitro vaccination.
Kather A; Ferrara A; Nonn M; Schinz M; Nieland J; Schneider A; Dürst M; Kaufmann AM
Int J Cancer; 2003 Apr; 104(3):345-53. PubMed ID: 12569558
[TBL] [Abstract][Full Text] [Related]
25. Identificaiton of Novel Immunogenic Human Papillomavirus Type 16 E7-Specific Epitopes Restricted to HLA-A*33;03 for Cervical Cancer Immunotherapy.
Kim S; Chung HW; Kong HY; Lim JB
Yonsei Med J; 2017 Jan; 58(1):43-50. PubMed ID: 27873494
[TBL] [Abstract][Full Text] [Related]
26. Phase I study of adjuvant immunotherapy with autologous tumor-infiltrating lymphocytes in locally advanced cervical cancer.
Huang H; Nie CP; Liu XF; Song B; Yue JH; Xu JX; He J; Li K; Feng YL; Wan T; Zheng M; Zhang YN; Ye WJ; Li JD; Li YF; Li JY; Cao XP; Liu ZM; Zhang XS; Liu Q; Zhang X; Liu JH; Li J
J Clin Invest; 2022 Aug; 132(15):. PubMed ID: 35727633
[TBL] [Abstract][Full Text] [Related]
27. Personalized peptide vaccination for cervical cancer patients who have received prior platinum-based chemotherapy.
Kawano K; Tsuda N; Waki K; Matsueda S; Hata Y; Ushijima K; Itoh K; Yamada A; Kamura T
Cancer Sci; 2015 Sep; 106(9):1111-7. PubMed ID: 26122553
[TBL] [Abstract][Full Text] [Related]
28. Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer.
Suzuki H; Fukuhara M; Yamaura T; Mutoh S; Okabe N; Yaginuma H; Hasegawa T; Yonechi A; Osugi J; Hoshino M; Kimura T; Higuchi M; Shio Y; Ise K; Takeda K; Gotoh M
J Transl Med; 2013 Apr; 11():97. PubMed ID: 23578144
[TBL] [Abstract][Full Text] [Related]
29. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
Santin AD; Bellone S; Palmieri M; Ravaggi A; Romani C; Tassi R; Roman JJ; Burnett A; Pecorelli S; Cannon MJ
Gynecol Oncol; 2006 Mar; 100(3):469-78. PubMed ID: 16249018
[TBL] [Abstract][Full Text] [Related]
30. Identification of promiscuous HPV16-derived T helper cell epitopes for therapeutic HPV vaccine design.
Grabowska AK; Kaufmann AM; Riemer AB
Int J Cancer; 2015 Jan; 136(1):212-24. PubMed ID: 24824905
[TBL] [Abstract][Full Text] [Related]
31. FOXM1 Contributes to Chemotherapy Sensitivity in Cervical Cancer by Regulating TTK.
Tang Q; Xu A; Yang Y; Zhang Y; Sun J
Discov Med; 2023 Jun; 35(176):208-220. PubMed ID: 37272088
[TBL] [Abstract][Full Text] [Related]
32. Maternal embryonic leucine zipper kinase: A novel biomarker and a potential therapeutic target of cervical cancer.
Wang J; Wang Y; Shen F; Xu Y; Zhang Y; Zou X; Zhou J; Chen Y
Cancer Med; 2018 Nov; 7(11):5665-5678. PubMed ID: 30334367
[TBL] [Abstract][Full Text] [Related]
33. MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma.
Engelhard VH; Obeng RC; Cummings KL; Petroni GR; Ambakhutwala AL; Chianese-Bullock KA; Smith KT; Lulu A; Varhegyi N; Smolkin ME; Myers P; Mahoney KE; Shabanowitz J; Buettner N; Hall EH; Haden K; Cobbold M; Hunt DF; Weiss G; Gaughan E; Slingluff CL
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32385144
[TBL] [Abstract][Full Text] [Related]
34. IgG response to MHC class I epitope peptides is a quantitative predictive biomarker in the early course of treatment of colorectal cancer using therapeutic peptides.
Kanekiyo S; Hazama S; Takenouchi H; Nakajima M; Shindo Y; Matsui H; Tokumitsu Y; Tomochika S; Tsunedomi R; Tokuhisa Y; Iida M; Sakamoto K; Suzuki N; Takeda S; Yamamoto S; Yoshino S; Okuno K; Udaka K; Kawakami Y; Matsueda S; Ito K; Nagano H
Oncol Rep; 2018 May; 39(5):2385-2392. PubMed ID: 29498403
[TBL] [Abstract][Full Text] [Related]
35. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer.
Chianese-Bullock KA; Irvin WP; Petroni GR; Murphy C; Smolkin M; Olson WC; Coleman E; Boerner SA; Nail CJ; Neese PY; Yuan A; Hogan KT; Slingluff CL
J Immunother; 2008 May; 31(4):420-30. PubMed ID: 18391753
[TBL] [Abstract][Full Text] [Related]
36. [Identification of T cell epitopes from ovarian cancer associated anti-idiotype antibody].
Li W; Cui H; Chang XH; Cheng HY; Cheng YX; Feng J; Fu TY
Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):764-9. PubMed ID: 19087545
[TBL] [Abstract][Full Text] [Related]
37. Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial.
Antonilli M; Rahimi H; Visconti V; Napoletano C; Ruscito I; Zizzari IG; Caponnetto S; Barchiesi G; Iadarola R; Pierelli L; Rughetti A; Bellati F; Panici PB; Nuti M
Int J Oncol; 2016 Apr; 48(4):1369-78. PubMed ID: 26892612
[TBL] [Abstract][Full Text] [Related]
38. TEX19 promotes ovarian carcinoma progression and is a potential target for epitope vaccine immunotherapy.
Xu Z; Tang H; Zhang T; Sun M; Han Q; Xu J; Wei M; Yu Z
Life Sci; 2020 Jan; 241():117171. PubMed ID: 31843525
[TBL] [Abstract][Full Text] [Related]
39. Epitope-Specific Immunotherapy Targeting CD4-Positive T Cells in Celiac Disease: Safety, Pharmacokinetics, and Effects on Intestinal Histology and Plasma Cytokines with Escalating Dose Regimens of Nexvax2 in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study.
Daveson AJM; Ee HC; Andrews JM; King T; Goldstein KE; Dzuris JL; MacDougall JA; Williams LJ; Treohan A; Cooreman MP; Anderson RP
EBioMedicine; 2017 Dec; 26():78-90. PubMed ID: 29191561
[TBL] [Abstract][Full Text] [Related]
40. Up-regulation of MELK by E2F1 promotes the proliferation in cervical cancer cells.
Sun H; Ma H; Zhang H; Ji M
Int J Biol Sci; 2021; 17(14):3875-3888. PubMed ID: 34671205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]